Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Body weight-range based initial dosing of ustekinumab in Crohn's disease: Is it an ideal approach?
Zhaopeng Huang, Lang Lin, Qing Li, et al.
Digestive and Liver Disease (2025)
Closed Access | Times Cited: 1
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Matthew C. Choy, C Li Wai Suen, Danny Con, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 11, pp. 981-996
Closed Access | Times Cited: 13
Diagnosis and management of inflammatory bowel disease
Lili Li, Rui Cheng, Yushan Wu, et al.
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 2, pp. 409-433
Closed Access | Times Cited: 11
Review article: Evidence‐based dietary management of inflammatory bowel disease
Peter R. Gibson, Chu K Yao, Emma P. Halmos
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1215-1233
Open Access | Times Cited: 9
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition
Yael Weintraub, Lauren V. Collen, Séamus Hussey, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International Survey
Mohmmed Tauseef Sharip, Biljana Brezina, Juan De La Revilla Negro, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 667-667
Open Access
Diffusion weighted imaging to predict longer term response in Crohn’s disease patients commencing biological therapy: Results from the MOTILITY Trial
Maira Hameed, Stuart A. Taylor, Norin Ahmed, et al.
British Journal of Radiology (2025)
Closed Access
Maintenance‐phase serum anti‐TNF levels are not associated with mucosal healing in pediatric Crohn's disease
Rinat Grabovski, Shirley Regev, Manar Matar, et al.
Journal of Pediatric Gastroenterology and Nutrition (2025)
Closed Access
Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine
Matthew B. Stanton, Mark Solinski, Stephen B. Hanauer
Expert Review of Clinical Immunology (2025), pp. 1-12
Closed Access
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease
María José Temido, Sailish Honap, Vipul Jairath, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access
Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients
Lívia Moreira Genaro, Juliana Carron, Marina Moreira de Castro, et al.
International Journal of Immunopathology and Pharmacology (2025) Vol. 39
Open Access
The content of memory T-cells in children with immune-mediated inflammatory disease with varying effectiveness of biological therapy
Т. В. Радыгина, С. В. Петричук, Д. Г. Купцова, et al.
Russian Pediatric Journal (2025) Vol. 28, Iss. 1, pp. 23-32
Open Access
ViT-Based Deep Learning and Unsupervised Clustering Analysis in Crohn's Disease Based on Body Composition to Identify Distinct Phenogroups and Predict Effectiveness of Anti-TNF Therapy
Yuexin Wang, Danhua Yao, Yuhua Huang, et al.
(2025)
Closed Access
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study within the UK NIHR Inflammatory Bowel Disease Bioresource
Christopher Roberts, Jaime Peters, Aleksejs Sazonovs, et al.
(2025)
Closed Access
Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn’s Disease Commencing Biological Therapy: The Motility Study
Andrew Plumb, Gordon W. Moran, Kashfia Chowdhury, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
The efficacy, safety, and persistence of vedolizumab versus adalimumab in patients with inflammatory bowel disease: a systematic review and meta-analysis
Zhixin Chen, Li Huo, Zhongzhuan Li, et al.
Inflammopharmacology (2025)
Closed Access
Persistence and Efficacy of Ustekinumab in Crohn’s Disease After Anti-TNF Failure: An Observational Study
I. Latras-Cortés, J. C. Sáez Hortelano, Patricia Suárez-Álvarez, et al.
Digestive Diseases and Sciences (2025)
Closed Access
The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring
Meenu Wadhwa, Isabelle Cludts, Eleanor Atkinson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
Neil Chanchlani, Richard K. Russell
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 93-94
Closed Access | Times Cited: 1
Current Status, Challenges, and Future Directions in Crohn’s Disease
Christian P. Selinger, Andrea E. van der Meulen–de Jong
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4699-4699
Open Access | Times Cited: 1
HLA-DQA1*05 associates with anti-TNF immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE UC and CD studies
Mark Reppell, Xiuwen Zheng, Ingeborg Dreher, et al.
Journal of Crohn s and Colitis (2024)
Closed Access | Times Cited: 1
Advancements in the management of pediatric inflammatory bowel disease
Jonathan O'Donnell, Sonia Thomas, Eric I. Benchimol
Expert Review of Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top